Kliniska prövningar
Sökresultat 1-10 av 192:
Din sökning: Kronisk obstruktiv lungsjukdom (KOL)
Följande termer användes i sökningen:
Kronisk obstruktiv lungsjukdom (KOL) (Pulmonary Disease, Chronic Obstructive)
Kartan visar var de kliniska prövningarna i resultatet är lokaliserade
-
1 :This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY 63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
Trial Locations: unknown Germany unknown
-
2 :Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)
Trial Locations: unknown Germany unknown
-
3 :To determine if ABX-IL8 will improve shortness of breath.
Trial Locations: Fremont United States California
-
4 :The purpose of this study is to evaluate the safety and effectiveness of yoga in reducing shortness of breath in people with chronic obstructive pulmonary disease (COPD). Patients in this study must have moderate to severe COPD and be primarily limited by shortness of breath.
Trial Locations: San Francisco United States California
-
5 :The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.
Trial Locations: New York City United States New York
-
6 :The purpose of this study is to examine genetic factors that influence the development of chronic obstructive pulmonary disease (COPD) in Hispanics, a minority group at high risk for the disease.
Trial Locations: San José Costa Rica San José
-
7 :The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.
Trial Locations: Birmingham United States Alabama, Birmingham United States Alabama, Birmingham United States Alabama, Charleston United States South Carolina, Greenville United States North Carolina, Houston United States Texas, Houston United States Texas, Los Angeles United States California, New Orleans United States Louisiana, Panama City United States Florida, Philadelphia United States Pennsylvania, Philadelphia United States Pennsylvania, Sepulveda United States California, Shreveport United States Louisiana, Spartanburg United States South Carolina, Waterbury United States Connecticut, West Haven United States Connecticut, unknown United States Florida, unknown United States New York
-
8 :The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
Trial Locations: Angleur Belgium Province de Liège, Brussels Belgium Région de Bruxelles-Capitale, Edegem Belgium Antwerpen, Gent Belgium Oost-Vlaanderen, Gent Belgium Oost-Vlaanderen, Hasselt Belgium Limburg, Malmédy Belgium Province de Liège, Menen Belgium West-Vlaanderen, Turnhout Belgium Antwerpen, Almelo Netherlands Overijssel, Breda Netherlands North Brabant, Heerenveen Netherlands Friesland, Heerlen Netherlands Limburg, Hengelo Netherlands Gelderland, Nijmegen Netherlands Gelderland, Zutphen Netherlands Gelderland, Bay Pines United States Florida, Birmingham United States Alabama, Charleston United States South Carolina, Charleston United States South Carolina, Coeur d'Alene United States Idaho, Fredericksburg United States Virginia, Harker Heights United States Texas, Hershey United States Pennsylvania, Houston United States Texas, Medford United States Oregon, New Britain United States Connecticut, New Hyde Park United States New York, Palo Alto United States California, Panama City United States Florida, Pembroke Pines United States Florida, Philadelphia United States Pennsylvania, Pittsburgh United States Pennsylvania, Reno United States Nevada, Richmond United States Virginia, San Diego United States California, Sepulveda United States California, Shreveport United States Louisiana, Spartanburg United States South Carolina, Tacoma United States Washington, Toledo United States Ohio, Torrance United States California, Wheat Ridge United States Colorado
-
9 :The purpose of this study is to determine whether carbon monoxide is effective in the treatment of stable COPD.
Trial Locations: unknown Netherlands Groningen
-
10 :The primary objective of this study is to compare the efficacy and safety of 200 ?g and 400 ?g of BE A 2180 to tiotropium 5 ?g and placebo when each is delivered by the Respimat Inhaler once daily for four weeks in patients with Chronic Obstructive Pulmonary Disease (COPD).
Trial Locations: Charleston United States South Carolina, Coeur d'Alene United States Idaho, Harker Heights United States Texas, Houston United States Texas, Lakewood United States California, Larchmont United States New York, Reno United States Nevada, Richmond United States Virginia, San Antonio United States Texas, Tacoma United States Washington, Wheat Ridge United States Colorado, Winston-Salem United States North Carolina, unknown United States Florida
UPP








